Program
enzalutamide
Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.
Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.
Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 313 open or running | phase 4since Oct 31, 2013 | Jan 18, 2011 | Apr 30, 2027phase 1 · NCT07783282 |
| Pfizerits history only | 162 open or running | phase 4since Nov 18, 2013 | Jul 31, 2007 | none ahead |
| Hinova Pharmaceuticalsits history only | 41 open or running | phase 3since Feb 17, 2019 | Dec 11, 2018 | none ahead |
| Alessa Therapeuticsits history only | 11 open or running | phase 1since Dec 14, 2023 | Dec 14, 2023 | Dec 30, 2028phase 1 · NCT06257693 |
| Applied Biologyits history only | 10 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Hinova Pharmaceuticals USAits history only | 10 open or running | phase 3since Feb 20, 2019 | Feb 20, 2019 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Astellas Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 15 studies since Jan 18, 2011.
- Apr 25, 2014Phase 2 study in Prostatic NeoplasmsNCT02124668 · 30 enrolled · Georgia, Russian Federation
- May 12, 20142 phase 1 studiesNCT02138162, NCT02138799
- Aug 22, 2014Phase 1 study in Prostatic NeoplasmsNCT02225093 · 12 enrolled · Moldova, Republic of
- Nov 7, 20142 phase 3 studiesNCT02288247, NCT02294461
- May 8, 2015Phase 4 study in Neoplasm MetastasisNCT02441517 · 4 enrolled · United States
- Aug 18, 2015Phase 2 study in Advanced Hepatocellular CarcinomaNCT02528643 · 165 enrolled · United States, Canada, Hong Kong and more
- Feb 5, 2016Phase 3 study in Metastatic Hormone Sensitive Prostate CancerNCT02677896 · 1,150 enrolled · United States, Argentina, Australia and more
- Feb 29, 2016Phase 2 study in Prostatic NeoplasmsNCT02799745 · 227 enrolled · United States, Canada
- Sep 27, 2016Phase 4 study in Prostatic NeoplasmsNCT02918968 · 206 enrolled · Japan
- Nov 7, 2016Phase 2 study in Prostatic NeoplasmsNCT02960022 · 900 enrolled · United States, Argentina, Australia and more
- Aug 20, 2018Phase 4 study in Metastatic Castration Resistant Prostate CancerNCT03641560 · 52 enrolled · India
- Aug 19, 2019Phase 3 study in Metastatic Hormone Sensitive Prostate CancerNCT04076059 · 180 enrolled · China
- Sep 17, 2019Phase 1 study in Prostatic NeoplasmsNCT04094519 · 24 enrolled · Moldova, Republic of
- Aug 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07783282 · 56 planned · Bulgaria
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07783282
- Jul 31, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT02960022
TargetBeta
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 31 Astellas Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07783282Prostatic Neoplasms · Bulgaria | 1 | Recruiting | Apr 30, 2027 | 56 |
| NCT04094519Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Dec 27, 2020 | 24 |
| NCT04076059Metastatic Hormone Sensitive Prostate Cancer · China | 3 | Active, not recruiting | Nov 18, 2022 | 180 |
| NCT03641560Metastatic Castration Resistant Prostate Cancer · India | 4 | Completed | Feb 20, 2024 | 52 |
| NCT02960022Prostatic Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Jul 31, 2029 | 900 |
| NCT02918968Prostatic Neoplasms · Japan | 4 | Completed | Mar 27, 2020 | 206 |
| NCT02799745Prostatic Neoplasms · United States, Canada | 2 | Completed | Aug 28, 2020 | 227 |
| NCT02677896Metastatic Hormone Sensitive Prostate Cancer · United States, Argentina, Australia and more | 3 | Completed | Oct 14, 2018 | 1,150 |
| NCT02528643Advanced Hepatocellular Carcinoma · United States, Canada, Hong Kong and more | 2 | Completed | Oct 2, 2017 | 165 |
| NCT02441517Neoplasm Metastasis · United States | 4 | Terminated | Mar 15, 2017 | 4 |
| NCT02294461Bulbo-Spinal Atrophy, X-Linked · China, Hong Kong, South Korea and more | 3 | Completed | Sep 20, 2015 | 395 |
| NCT02288247Neoplasm Metastasis · Austria, Belgium, Czechia and more | 3 | Completed | Apr 30, 2020 | 688 |
| NCT02225093Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Feb 3, 2014 | 12 |
| NCT02138799Drug-Drug Interaction (DDI) · Germany | 1 | Completed | Sep 2013 | 28 |
| NCT02138162Severe Hepatic Impairment · Bulgaria | 1 | Completed | Mar 2014 | 16 |
| NCT02124668Prostatic Neoplasms · Georgia, Russian Federation | 2 | Completed | May 25, 2017 | 30 |
| NCT02116582Metastatic Castration-Resistant Prostate Cancer · Belgium, France, Germany and more | 4 | Completed | May 8, 2016 | 215 |
| NCT02091960Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Feb 28, 2017 | 103 |
| NCT01977651Seizures · United States, Argentina, Australia and more | 4 | Completed | Feb 1, 2016 | 424 |
| NCT01913379Healthy Subjects · France | 1 | Completed | Dec 2011 | 41 |
| NCT01911741Healthy Subjects · Germany | 1 | Completed | Mar 2013 | 55 |
| NCT01911728Pharmacokinetics of MDV3100 · South Africa | 1 | Completed | Feb 21, 2012 | 14 |
| NCT01911715Healthy Subjects · Netherlands | 1 | Completed | Jul 2011 | 6 |
| NCT01902251Prostatic Neoplasms · United States | 1 | Completed | Oct 2013 | 27 |
| NCT01901133Kidney Diseases · Moldova, Republic of | 1 | Completed | Jan 2012 | 33 |
| NCT01663415Neoplasms | 2 | Withdrawn | Oct 2014 | 0 |
| NCT01650194Neoplasms · United States | 2 | Completed | Jan 4, 2018 | 60 |
| NCT01534052Prostatic Neoplasms · United States, Moldova, Republic of, South Africa | 2 | Completed | Apr 18, 2017 | 52 |
| NCT01302041Prostatic Neoplasms · Belgium, Czechia, Denmark and more | 2 | Completed | Jul 29, 2012 | 67 |
| NCT01288911Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Oct 19, 2014 | 375 |
| NCT01284920Prostatic Neoplasms · Japan | 2 | Completed | Jul 12, 2012 | 47 |
How it is read
Names in the registry
- “Enzalutamide”, 40 entries
- “enzalutamide”, 13 entries
- “MDV3100”, 8 entries
- “HC-1119”, 4 entries
- “HC1119”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 41 studies
- Neoplasms, 6 studies
- Breast Neoplasms, 5 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.